Children's Oncology Group's 2023 blueprint for research: Rare tumors-Reference-Cited by-同舟云学术

Children's Oncology Group's 2023 blueprint for research: Rare tumors

Published:2023-07-17 Issue:S6 Volume:70 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Schultz Kris Ann P.¹^ORCID,Chintagumpala Murali²,Piao Jin³,Chen Kenneth S.⁴^ORCID,Gartrell Robyn⁵^ORCID,Christison‐Lagay Emily⁶,Berry Jesse L.⁷^ORCID,Shah Rachana⁸^ORCID,Laetsch Theodore W.⁹^ORCID,

Affiliation:

1. Cancer and Blood Disorders Children's Minnesota Minneapolis Minnesota USA

2. Division of Hematology‐Oncology Department of Pediatrics Texas Children's Cancer Center Baylor College of Medicine Houston Texas USA

3. University of Southern California Keck School of Medicine Los Angeles California USA

4. Department of Pediatrics UT Southwestern Medical Center Dallas Texas USA

5. Division of Pediatric Hematology/Oncology Department of Pediatrics Columbia University Irving Medical Center New York New York USA

6. Division of Pediatric Surgery Yale School of Medicine Yale New‐Haven Children's Hospital New Haven Connecticut USA

7. The Vision Center Children's Hospital Los Angeles, The Saban Research Institute, Children's Hospital Los Angeles, USC Roski Eye Institute, Norris Comprehensive Cancer Center, Keck School of Medicine University of Southern California Los Angeles California USA

8. Division of Hematology‐Oncology Department of Pediatrics Cancer and Blood Disease Institute Children's Hospital Los Angeles Keck School of Medicine University of Southern California Los Angeles California USA

9. Division of Oncology Children's Hospital of Philadelphia University of Pennsylvania Philadelphia Pennsylvania USA

Abstract

AbstractThe Children's Oncology Group (COG) Rare Tumor Committee includes the Infrequent Tumor and Retinoblastoma subcommittees, encompassing a wide range of extracranial solid tumors that do not fall within another COG disease committee. Current therapeutic trial development focuses on nasopharyngeal carcinoma, adrenocortical carcinoma, pleuropulmonary blastoma, colorectal carcinoma, melanoma, and thyroid carcinoma. Given the rarity of these tumors, novel strategies and international collaborative efforts are necessary to advance research and improve outcomes.

Funder

U.S. Department of Defense

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/am-pdf/10.1002/pbc.30574

Reference76 articles.

1. Nasopharyngeal carcinoma in children: Retrospective review of 50 patients

2. The national cancer data base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma

3. Nasopharyngeal Cancer Among Young People in the United States: Racial Variations by Cell Type

4. Childhood nasopharyngeal carcinoma: from biology to treatment

5. Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children’s Oncology Group ARAR0331 Study

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rare tumors II: Adrenocortical tumors, neuroendocrine tumors of the appendix, pheochromocytoma and paraganglioma, pancreatoblastoma and solid pseudopapillary tumors of the pancreas;Pediatric Blood & Cancer;2024-07-21

2. The Next Chapter in Immunotherapy and Radiation Combination Therapy: Cancer-Specific Perspectives;International Journal of Radiation Oncology*Biology*Physics;2024-04